When an early-stage investor passes on a medtech deal, the reason is often a specific risk that surfaced in diligence and that the founder hadn't addressed or couldn't answer cleanly. Many of those risks are knowable before you raise, and much of what an investor checks is in public records.
Here are five areas an investor typically checks early, what the public record can show, and how to address each before the raise.
1 Regulatory pathway clarity
The first question is simple: do you know your pathway, and is it the right one? A founder who says "we'll do a 510(k)" for a device with no clean predicate, or who is unclear whether they are Class II or Class III, signals risk immediately. Investors check FDA's 510(k) and PMA databases for your class, your predicate and how comparable devices reached the market.
How to close it
Name your pathway, your predicate if you have one (with its 510(k) or De Novo number), and your evidence basis before the first meeting. If you are pre-submission, a documented Q-Sub plan beats a confident guess.
2 Clinical evidence depth
Investors map your claims against what the clinical record can actually support. Registered trials are public on ClinicalTrials.gov, including their status and, for stopped trials, often the reason given. A thin evidence base can be acceptable at seed, but only if the plan to build it is specific (endpoints, sample size, sites, timeline), not aspirational.
How to close it
Show the evidence ladder: what you have, what the next readout proves, and when. Tie each marketing claim to the study that will support it.
3 IP defensibility
A patent number is not a moat. Investors look at whether your filings actually cover the product as built, how crowded the space is, and whether a fast-follower could design around you. The USPTO record tells most of this story.
How to close it
Be able to explain, in one paragraph, what your core claims protect and what they do not. Acknowledge the whitespace honestly — investors trust founders who know their own gaps.
4 Reimbursement path
A cleared device with no coverage and no code has a hard road to becoming a business. Investors check CMS coverage determinations and the CPT landscape for whether someone will pay for your device once it ships; see our article on the reimbursement question.
The trap
"We'll figure out reimbursement after clearance" reads as an unmanaged risk. Even a directional coverage thesis — comparable codes, payer logic, the gap you'll need to close — beats silence.
5 Team & execution credibility
Finally: has this team done a version of this before? Investors look for operators who have navigated FDA, scaled manufacturing, or carried a comparable device to market. Prior-company history is largely public — and it cuts both ways, so frame it honestly.
How to close it
Name the relevant experience explicitly. If there's a gap (e.g. no regulatory lead), show the hiring plan and the advisors filling it in the interim.
What diligence can — and can't — tell you
An honest assessment will not promise that closing these five risks guarantees a raise; no assessment does, and anyone who claims to predict your outcome is selling you something. What it can do is show you exactly what an investor will find before they find it — every figure traceable to a public source you can verify yourself — so you walk into the room having already answered the hard questions.
That is the entire point of pre-raise diligence: not a score, but a navigation map. Diagnose the risk, show the path to close it, and arrive prepared.
References
- FDA. "510(k) Premarket Notification" database. accessdata.fda.gov
- FDA. "Premarket Approval (PMA)" database. accessdata.fda.gov
- National Library of Medicine. ClinicalTrials.gov. clinicaltrials.gov
- USPTO. "Patent Public Search." uspto.gov
- CMS. "Medicare Coverage Database." cms.gov
See what an investor will find — first
Start with a free 20-minute call, or buy an automated Quick Screen for a cited first read on your company's competitive and regulatory record, drawn from public sources.